Wegovy, Novo Nordisk’s weight management drug, was approved for adolescent use in December 2022, and by the next month, the American Academy of Pediatrics recommended weight loss drugs for children with obesity who are at least 12.
Health technology company Komodo Health compiled U.S. insurance claims data to find the prescriptions. The results show a willingness to embrace the GLP-1 but also opportunity for more patients, since forecasts show about 14.7 million U.S. children have obesity, Reuters reported.
Past research has found nearly 1 in 10 children have used nonprescription weight loss products that are ineffective and potentially harmful. In late 2023, a social media trend also promoted “budget Ozempic,” or the use of laxatives and stool softeners for weight loss.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.